194 related articles for article (PubMed ID: 33686251)
1. The evolving concept of indications for allogeneic hematopoietic cell transplantation during first complete remission of acute myeloid leukemia.
Yanada M
Bone Marrow Transplant; 2021 Jun; 56(6):1257-1265. PubMed ID: 33686251
[TBL] [Abstract][Full Text] [Related]
2. T cells reloaded after allogeneic HCT.
Bornhäuser M
Blood; 2023 Apr; 141(14):1652-1653. PubMed ID: 37022734
[No Abstract] [Full Text] [Related]
3. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
4. Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.
Walter RB; Ofran Y; Wierzbowska A; Ravandi F; Hourigan CS; Ngai LL; Venditti A; Buccisano F; Ossenkoppele GJ; Roboz GJ
Leukemia; 2021 Jun; 35(6):1529-1538. PubMed ID: 33758317
[TBL] [Abstract][Full Text] [Related]
5. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.
Stahl M; Menghrajani K; Derkach A; Chan A; Xiao W; Glass J; King AC; Daniyan AF; Famulare C; Cuello BM; Horvat TZ; Abdel-Wahab O; Levine RL; Viny AD; Stein EM; Cai SF; Roshal M; Tallman MS; Goldberg AD
Blood Adv; 2021 Mar; 5(5):1552-1564. PubMed ID: 33687434
[TBL] [Abstract][Full Text] [Related]
6. Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017.
Sasaki K; Jabbour E; Short NJ; Jain N; Ravandi F; Pui CH; Kantarjian H
Am J Hematol; 2021 Jun; 96(6):650-658. PubMed ID: 33709456
[TBL] [Abstract][Full Text] [Related]
7. Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome.
Williams L; Doucette K; Karp JE; Lai C
Bone Marrow Transplant; 2021 Jul; 56(7):1535-1549. PubMed ID: 33686252
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Daher-Reyes G; Kim T; Novitzky-Basso I; Kim KH; Smith A; Stockley T; Capochichi JM; Al-Shaibani Z; Pasic I; Law A; Lam W; Michelis FV; Gerbitz A; Viswabandya A; Lipton J; Kumar R; Mattsson J; Schimmer A; McNamara C; Murphy T; Maze D; Gupta V; Sibai H; Chan S; Yee K; Minden M; Zhang Z; Schuh A; Kim DDH
Bone Marrow Transplant; 2021 Aug; 56(8):1908-1918. PubMed ID: 33767401
[TBL] [Abstract][Full Text] [Related]
9. Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.
Bouvier A; Hamel JF; Delaunay J; Delabesse E; Dumas PY; Ledoux MP; Peterlin P; Luquet I; Roth Guepin G; Bulabois CE; Gallego Hernanz MP; Guillerm G; Guieze R; Hicheri Y; Simand C; Himberlin C; Hunault-Berger M; Bernard M; Jourdan E; Caillot D; Dorvaux V; Tavernier E; Daguindau E; Banos A; Ojeda-Uribe M; Gyan E; Alexis M; Marolleau JP; Turlure P; Bouscary D; Humbrecht C; Zerazhi H; Béné MC; Pigneux A; Carre M; Ifrah N; Blanchet O; Vey N; Récher C; Cornillet-Lefèbvre P;
Eur J Haematol; 2021 Jul; 107(1):111-121. PubMed ID: 33765335
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
11. Effect of extramedullary disease on allogeneic hematopoietic cell transplantation for pediatric acute myeloid leukemia: a nationwide retrospective study.
Sakaguchi H; Miyamura T; Tomizawa D; Taga T; Ishida H; Okamoto Y; Koh K; Yokosuka T; Yoshida N; Sato M; Noguchi M; Okada K; Hori T; Takeuchi M; Kosaka Y; Inoue M; Hashii Y; Atsuta Y
Bone Marrow Transplant; 2021 Aug; 56(8):1859-1865. PubMed ID: 33692532
[TBL] [Abstract][Full Text] [Related]
12. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.
Lin TL; Rizzieri DA; Ryan DH; Schiller GJ; Kolitz JE; Uy GL; Hogge DE; Solomon SR; Wieduwilt MJ; Ryan RJ; Faderl S; Cortes JE; Lancet JE
Blood Adv; 2021 Mar; 5(6):1719-1728. PubMed ID: 33724305
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukaemia in patients we judge as being older and/or unfit.
Lazarevic VL
J Intern Med; 2021 Aug; 290(2):279-293. PubMed ID: 33780573
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on current survival and new developments in AML.
Rowe JM
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101248. PubMed ID: 33762103
[TBL] [Abstract][Full Text] [Related]
15. Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML).
Hochman MJ; Othus M; Walter RB; Shaw C; Gardner K; Percival MM; Halpern AB; Hendrie PC; Sandmaier BM; Estey EH
Leuk Lymphoma; 2021 Jun; 62(6):1532-1535. PubMed ID: 33752557
[No Abstract] [Full Text] [Related]
16. New Treatment Options for Older Patients with Acute Myeloid Leukemia.
Saxena K; Konopleva M
Curr Treat Options Oncol; 2021 Mar; 22(5):39. PubMed ID: 33743079
[TBL] [Abstract][Full Text] [Related]
17. Outcome of T-cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Koc Y; Angelucci E; Tischer J; Arat M; Pioltelli P; Bernasconi P; Chiusolo P; Diez-Martin JL; Sanz J; Ciceri F; Peric Z; Giebel S; Canaani J; Mohty M
Cancer; 2021 Jul; 127(14):2507-2514. PubMed ID: 33739471
[TBL] [Abstract][Full Text] [Related]
18. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
Penter L; Zhang Y; Savell A; Huang T; Cieri N; Thrash EM; Kim-Schulze S; Jhaveri A; Fu J; Ranasinghe S; Li S; Zhang W; Hathaway ES; Nazzaro M; Kim HT; Chen H; Thurin M; Rodig SJ; Severgnini M; Cibulskis C; Gabriel S; Livak KJ; Cutler C; Antin JH; Nikiforow S; Koreth J; Ho VT; Armand P; Ritz J; Streicher H; Neuberg D; Hodi FS; Gnjatic S; Soiffer RJ; Liu XS; Davids MS; Bachireddy P; Wu CJ
Blood; 2021 Jun; 137(23):3212-3217. PubMed ID: 33720354
[TBL] [Abstract][Full Text] [Related]
19. Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia.
Othus M; Garcia-Manero G; Godwin J; Weick J; Stirewalt D; Appelbaum F; Erba H; Estey E
Leuk Lymphoma; 2021 Aug; 62(8):1967-1972. PubMed ID: 33719833
[TBL] [Abstract][Full Text] [Related]
20. Oral Azacitidine Maintenance for Acute Myeloid Leukemia.
Perissinotti AJ; Benitez LL; Marini BL
N Engl J Med; 2021 Apr; 384(13):e51. PubMed ID: 33789022
[No Abstract] [Full Text] [Related]
[Next] [New Search]
